Superior Mesenteric Artery Thrombosis Following Severe COVID-19 Pneumonia


Authors: Abdulhadi A Alali,1Mohammed O Baqais,2Fayez M Albishi,3, et. al. Cureus. (11):19954. doi: 10.7759/cureus.19954PMCID: PMC8713302PMID: 34976537 Abstract Thrombotic events are well-recognized complications of coronavirus disease 2019 (COVID-19). The incidence of such complications is highly related to the severity of COVID-19 pneumonia. Recent evidence suggests that the coagulopathy of COVID-19 may persist for some period even after the full recovery from […]

Treatment of Long COVID symptoms with triple anticoagulant therapy


Gert J Laubscher, M Asad Khan, Chantelle Venter, Jan H Pretorius, and 2 more, This is a preprint; it has not been peer reviewed by a journal. https://doi.org/10.21203/rs.3.rs-2697680/v1 Research Square Abstract Background: Fibrin(ogen) amyloid microclots and platelet hyperactivation are key pathological findings in patients with acute COVID-19 infection and also in those with Long COVID/Post-Acute Sequelae […]

UK scientists find link between proteins related to blood clots and long Covid


Biomarker discovery indicates that sufferers from brain fog and fatigue post-virus could be treated with anticoagulants Oksana Pyzik 31 Aug 2023 The Guardian Scientists have identified molecular signatures in the blood that are linked to brain fog, other cognitive problems and fatigue in patients who are diagnosed with long Covid after catching the virus. Raised levels of […]

COVID-19 vaccines and thrombosis with thrombocytopenia syndrome


Authors: Chih-Cheng Lai 1, Wen-Chien Ko 2, Chih-Jung Chen 3, Po-Yen Chen 4, Yhu-Chering Huang 3, Ping-Ing Lee 5, Po-Ren Hsueh 6 7 Abstract Introduction: To combat COVID-19, scientists all over the world have expedited the process of vaccine development. Although interim analyses of clinical trials have demonstrated the efficacy and safety of COVID-19 vaccines, a serious but rare adverse event, thrombosis with thrombocytopenia syndrome (TTS), has been reported following […]

Anticoagulation in COVID-19: current concepts and controversies


Authors: http://orcid.org/0000-0002-3809-8926Atanu Chandra1, 6289Uddalak Chakraborty2, Shrestha Ghosh1, Sugata Dasgupta3 Abstract Rising incidence of thromboembolism secondary to COVID-19 has become a global concern, with several surveys reporting increased mortality rates. Thrombogenic potential of the SARS-CoV-2 virus has been hypothesised to originate from its ability to produce an exaggerated inflammatory response leading to endothelial dysfunction. Anticoagulants have remained the primary […]

Better Anticoagulated Than Not! Hypercoagulability in COVID-19


Authors: Dhauna P. Karam, MD1 Incidence of thrombotic complications in patients with COVID-19 who are critically ill is high, with an estimated incidence of 31% for arterial or venous thromboembolism (VTE), acute pulmonary embolism, ischemic stroke, and myocardial infarction. On the basis of the study by Klok et al,1 pulmonary embolism was the most common thrombotic […]